Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million

PR Newswire December 22, 2020

REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE(TM) Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

PR Newswire December 10, 2020

REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II

PR Newswire December 9, 2020

REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I

PR Newswire December 1, 2020

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire November 23, 2020

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting

PR Newswire November 10, 2020

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire November 5, 2020

REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights

PR Newswire November 4, 2020

REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

PR Newswire October 28, 2020

REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG

PR Newswire October 27, 2020

REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

PR Newswire September 30, 2020

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire September 25, 2020

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire September 14, 2020

REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE(TM) Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

PR Newswire September 9, 2020

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire September 2, 2020

REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

PR Newswire August 25, 2020

REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights

PR Newswire August 6, 2020

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

PR Newswire August 4, 2020

REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

PR Newswire July 30, 2020

REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases

PR Newswire July 8, 2020